Repligen (RGEN) Tops Q4 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
February 17, 2022 7:30 AM ESTRecord revenue of $186.5 million for the quarter, and year-over-year growth of 72%
Record revenue of $670.5 million for the year, and year-over-year growth of 83%
Organic revenue growth of 69% for the fourth quarter and 71% for the year 2021
Completes acquisition of single-use fluid management component manufacturer BioFlex Solutions
WALTHAM, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2021. Provided in this press release are... More
